Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Rituximab (Primary) ; Bendamustine; Pentostatin
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 14 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 14 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.